Day: September 19, 2022

Coherent Thought Leaders to Present at ECOC 2022 and Showcase New Products With Live Technology Demonstrations

Written by Customer Service on September 19, 2022. Posted in Public Companies.

PITTSBURGH, Sept. 19, 2022 (GLOBE NEWSWIRE) — Coherent Corp. (Nasdaq: COHR), the world’s leading supplier of components and modules for optical communications, today announced that it is exhibiting at ECOC 2022 in Basel, Switzerland, Sept. 19-21, booth #1. Coherent thought leaders will present at ECOC’s Market Focus on advanced technologies for optical networks as follows:800G and 1.6T Upgrade Cycles for Datacom: Continued Significance of Direct DetectionVipul Bhatt – VP, Marketing, Datacom VerticalTuesday, Sept. 20, 15:45-16:05 CESTAdvanced ROADM Architectures With Ultrahigh-Resolution Telemetry for High-Mix Wavelength Services Dr. Jack Jian Xu – VP, Marketing, Telecom VerticalWednesday, Sept. 21, 10:20-10:40 CESTCoherent Optics in Client Pluggable Form Factor Enables IP-over-DWDM in Disaggregated Transport...

Notice of redemption of convertible bonds PKG4

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Notice of redemption of convertible bonds PKG4 AS Pro Kapital Grupp informs that it is redeeming 27 999 “EEK 7.00 PRO KAPITAL GRUPP CONV. BOND PKG4 10-2020” convertible bonds (with ISIN EE3300109248) in total nominal value of 279 990 Estonian kroons and issue value of 78 397.20 euros and has submitted the Nasdaq Central Depository of Securities the application to delete the bonds from the register. The convertible bonds bore an annual interest of 7%. The issue price of each convertible bond was 2.80 euros. The list of bondholders was fixed on 16 September 2022 and redemption payment will be made on 30 September 2022. Edoardo Axel Preatoni Member of the Management Board +372 614 4920prokapital@prokapital.ee

Notice of redemption of convertible bonds PKG4

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Proactive news headlines including Astro Resources, Aeris Resources, Buru Energy and Animoca Brands Corporation

Written by Customer Service on September 19, 2022. Posted in Mergers And Acquisitions.

Sydney, Sept. 19, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Astro Resources NL (ASX:ARO) has revealed a significant increase in indicated resources to 78 million tonnes at 4.8% THM (total heavy minerals) at its Governor Broome Heavy Mineral Sands Project in Western Australia. Click here Aeris Resources Ltd (ASX:AIS) has further enhanced the copper potential of Murrawombie deposit within the Tritton operations in New South Wales with high-grade copper intersected below the resource. Click here Buru Energy Ltd (ASX:BRU) has responded to news that Origin Energy intends to exit upstream exploration permits and divest 50% of its joint venture interests with Buru in the Canning Basin. Click here Animoca Brands Corporation...

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE MeetingDasiglucagon significantly reduced the requirement for intravenous glucose to maintain glycemia in newborns and infants with CHI (Part 1 of Phase 3 trial) Dasiglucagon reduced time in hypoglycemia and enabled discontinuation of intravenous glucose in most infants and limited the need for pancreatectomy (Part 2 of Phase 3 trial) Results support the potential for dasiglucagon to be a novel, effective, and well tolerated treatment for infants with CHI dependent on intravenous glucoseCopenhagen, DK and Boston MA, U.S. September 19, 2022 – Zealand Pharma A/S (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today...

INVL Partner Global Infrastructure Fund I raised an additional USD 1.895 million

Written by Customer Service on September 19, 2022. Posted in Public Companies.

The INVL Partner Global Infrastructure Fund I, which invests in a fund of infrastructure assets managed by a company of global stature with a long track record, raised another USD 1.895 million from 7 investors. An offering of the fund’s investment units ended on 15 September, bringing the capital raised to date by the INVL Partner Global Infrastructure Fund I to USD 39.390 million. A total of 95 investors have invested in the fund which invests in infrastructure in member states of the Organisation for Economic Co-operation and Development (OECD). “Investor sentiment in the capital markets is still weighed down not just by the war in Ukraine but also by inflation, rising interest rates and slowing economic growth. But investors notice alternative ideas for investing in world-class funds, diversifying their portfolios and protecting...

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

Written by Customer Service on September 19, 2022. Posted in Mergers And Acquisitions.

Further consolidates GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF) Significantly expands GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE) Combines Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthen and accelerate research and development Deal terms include a payment of CHF40 million, an aggregate of CHF65 million of potential additional payments contingent on successful clinical and regulatory milestones, and one-third of the net proceeds from the potential sale of a Priority Review Voucher, if awarded by the FDA GENFIT will host a live...

Bureau Veritas: acquisition of Galbraith Laboratories Inc., a US expert in Healthcare analytical testing solutions

Written by Customer Service on September 19, 2022. Posted in Mergers And Acquisitions.

PRESS RELEASE Neuilly-sur-Seine, France – September 19, 2022 Bureau Veritas acquires Galbraith Laboratories Inc., a US expert in Healthcare analytical testing solutions Expanding BV’s position in Consumer Healthcare, Personal Care & Industrial Chemical markets Bureau Veritas, a world leader in testing, inspection and certification, announced the acquisition of Galbraith Laboratories Inc., an expert in advanced analytical solutions in North America. The acquisition will further position Bureau Veritas in the Consumer Healthcare and Industrial Chemical supply chain by connecting our existing services to support upstream research and product development through manufacturing to the end consumer. Galbraith Laboratories Inc. offers testing solutions to a wide range of industry segments, including chemicals, healthcare, cosmetics, consumer,...

European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with aflibercept In addition, patients treated with Vabysmo received up to 33% fewer median number of injections compared to aflibercept Reducing the number of eye injections over time could offer a less burdensome treatment schedule for individuals, their caregivers and healthcare systems Vabysmo simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditionsBasel, 19 September 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) approved Vabysmo® (faricimab) for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD)...

Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022The target number of 38 patients have been enrolled at clinical sites in France, Germany, the UK, the Netherlands, and Italy Waiting list for additional patients initiated to replace potential pre-implantation drop-outs and ineligibility Implantations due to be completed by the end of 2022; PRIMAvera read-out expected around the end of 2023Paris, France, September 19, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the completion of patient enrollment in the PRIMAvera pivotal...

Day: September 19, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice